Daliresp and Head injury - a phase IV clinical study of FDA data

Summary:

Head injury is reported as a side effect among people who take Daliresp (roflumilast), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Spiriva, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Head injury when taking Daliresp. It is created by eHealthMe based on reports of 4,674 people who have side effects when taking Daliresp from the FDA, and is updated regularly.

What is Daliresp?

Daliresp has active ingredients of roflumilast. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 4,722 Daliresp users. Check the latest studies of Daliresp.

What is Head injury?

Head injury is found to be associated with 2,627 drugs and 3,250 conditions by eHealthMe. Check the latest studies of Head injury.

On Aug, 03, 2026

4,674 people reported to have side effects when taking Daliresp.
Among them, 58 people (1.24%) have Head injury.

Among these 58 people:

How long have people been on Daliresp when they have Head injury? *

What is the gender of people who have Head injury when taking Daliresp? *

female: 61.4 %
male: 38.6 %

What is the age of people who have Head injury when taking Daliresp? *

What are other drugs people take besides Daliresp? *

What are other side effects people have besides Head injury? *

Dyspnea (difficult or laboured breathing): 16 people, 27.59%
Fatigue (feeling of tiredness): 16 people, 27.59%
Fall: 14 people, 24.14%
Pneumonia: 12 people, 20.69%
Back Pain: 12 people, 20.69%
Sinusitis (inflammation of sinus): 12 people, 20.69%
Headache (pain in head): 11 people, 18.97%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 11 people, 18.97%
Pain: 11 people, 18.97%
Urinary Tract Infection: 10 people, 17.24%

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 13 people, 22.41%
High Blood Pressure: 6 people, 10.34%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 5 people, 8.62%
Pain: 4 people, 6.90%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 4 people, 6.90%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 3.45%
Panic Disorder: 2 people, 3.45%
Constipation: 2 people, 3.45%
Colon Cancer: 2 people, 3.45%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 2 people, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Daliresp and have Head injury?

- Check whether Head injury is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Daliresp:

Daliresp (4,722 reports)

Head injury treatments and more:

Head injury (160,560 reports)

Browse all side effects of Daliresp:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Head injury:

Head injury (2,627 drugs)

Browse all the conditions that are associated with Head injury:

Head injury (3,250 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on roflumilast (the active ingredients of Daliresp) and Daliresp (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.